and Media

News Releases

Portola Pharmaceuticals to Host Analyst and Investor Day on November 19

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced today that it will host an Analyst and Investor Day on Thursday, November 19. The event is scheduled to take place from 8-11:30 a.m. Eastern Time in New York and will be simultaneously webcast.  

Members of Portola’s senior management team will provide an update on recent advances with the Company’s thrombosis and hematologic cancer product pipeline. In addition, the following experts in the field of thrombosis will participate:  

  • Alexander (Ander) T. Cohen, MBBS, M.Sc., M.D., Consultant Physician and Epidemiologist, Department of Hematological Medicine, King’s College London
  • Stuart J. Connolly, M.D. Professor Emeritus of Medicine, McMaster University, Hamilton Health Sciences
  • C. Michael Gibson, M.S., M.D., Professor of Medicine, Harvard Medical School, PERFUSE Study Group, Beth Israel Deaconess Medical Center

Webcast Information
The live webcast will start at 8:00 a.m. Eastern Time. To access the live and subsequently archived webcast, go to the Investor Relations section of the company's website at A replay will be available for 30 days following the live event.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing its three wholly-owned programs using novel biomarker and genetic approaches that may increase the likelihood of clinical, regulatory and commercial success of its potentially life-saving therapies. These programs include betrixaban, an oral, once-daily Factor Xa inhibitor being evaluated in the APEX Phase 3 study for prophylaxis of venous thromboembolism; andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit and follow the Company on Twitter @Portola_Pharma.                                                                                               


Investor Contact:
Ana KaporPortola

Media Contact:
Julie NormartW2O 

Primary Logo

Portola Pharmaceuticals, Inc.